Sareum Holdings (SAR) AI Stock Analysis

• Market Cap: £21.40M
• Dividend Yield: N/A
• Average Volume (3M): 619.72K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.66
• Revenue Growth: N/A
• EPS Growth: 23.76%
• Country: UK
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 138,065,170
• 10 Day Avg. Volume: 1,134,615
• 30 Day Avg. Volume: 619,716
• PEG Ratio: 0.31
• Price to Book (P/B): 8.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.02
• Revenue Forecast (FY): £43.15M

• Rating: 42 Neutral
• Price Target: 14.00p ▼(-6.67% Downside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is primarily constrained by weak financial performance (pre-revenue with persistent losses and continued cash burn) and bearish technical signals (below key moving averages with negative MACD). Valuation provides limited support because the company is loss-making and no dividend yield is available.

Positive Factors

No reported debt

A debt-free balance sheet materially reduces fixed financial obligations and interest exposure for a small biotech. Over a 2–6 month horizon this preserves flexibility to time licensing deals or equity raises, lowers bankruptcy risk, and supports continued R&D investment without servicing debt.

Asset monetisation/licensing model

Relying on licensing and collaborations is a durable strategic fit for an early-stage discovery company: it outsources costly late-stage development, creates milestone/royalty upside, and lets Sareum monetise successes without building large commercial infrastructure — a structural advantage for capital-constrained biotechs.

Narrowing cash outflow

A reduction in cash outflow, even if still negative, indicates improving operational discipline or timing of spend. This trend lengthens runway and lowers near-term financing urgency, making it easier to execute partnership negotiations and advance selected programs over the coming months.

Negative Factors

Pre-revenue and widening losses

Being pre-revenue with widening losses is a core structural weakness: the business cannot self-fund R&D or operations, dependability of future income is tied to uncertain milestones or licensing, and persistent losses depress returns and limit reinvestment capacity over the medium term.

Persistent negative cash flow

Sustained negative operating and free cash flow means ongoing external financing is required. This creates runway and dilution risk, constrains strategic optionality, and forces management to prioritise near-term funding events over long‑term scientific choices, affecting program continuity and partner bargaining power.

Small, volatile equity and assets

Small, volatile equity and asset bases signal dependence on episodic funding rounds and make the company vulnerable to timing mismatches. This limited scale reduces resilience to R&D setbacks, weakens creditability in partner negotiations, and raises the probability of dilution or asset sales to maintain operations.

Sareum Holdings Business Overview & Revenue Model

Company Description

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

How the Company Makes Money

Sareum Holdings generates revenue primarily through licensing agreements and collaborations with pharmaceutical companies. The company partners with larger organizations to co-develop its drug candidates, sharing the costs and risks associated with clinical trials and commercialization. Sareum typically receives upfront payments, milestone payments based on the achievement of development goals, and potential royalties on sales if the drugs reach the market. Additionally, the company may engage in research collaborations that provide funding and resources to advance its drug discovery projects.

Sareum Holdings Financial Statement Overview

Summary

Income statement is weak due to effectively zero revenue and persistent (widening) losses, and cash flow shows ongoing negative operating and free cash flow despite some recent narrowing of outflows. The main offset is a cleaner balance sheet with no reported debt, but the company remains dependent on external funding.

Income Statement

Sareum Holdings remains pre-revenue (revenue is effectively zero in recent annual periods), with persistent operating losses and negative EBITDA/EBIT each year. Net losses have widened versus earlier years, indicating a heavier cost base without offsetting commercial income. While loss-making is common in biotechnology, the lack of visible revenue traction keeps profitability and earnings quality weak.

Balance Sheet

The balance sheet shows no reported debt, which reduces financial risk and provides flexibility. However, equity is relatively small and has been volatile over time, and returns on equity are consistently negative due to ongoing losses. Asset levels also fluctuate meaningfully year to year, underscoring dependence on funding cycles rather than internally generated growth.

Cash Flow

Cash burn remains significant, with operating cash flow and free cash flow negative across all periods. There is some improvement in the most recent year (cash outflow narrowed versus the prior year), but the business is still not self-funding. Free cash flow closely tracks net losses, reinforcing that ongoing operations require external financing until revenues emerge.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-1.00K	-1.00K	-2.00K	-1.09K
EBITDA	-3.38M	-4.54M	-4.01M	-2.57M	-1.70M
Net Income	-4.44M	-3.42M	-3.19M	-2.17M	-1.50M
Balance Sheet
Total Assets	4.23M	2.77M	2.02M	4.79M	3.08M
Cash, Cash Equivalents and Short-Term Investments	3.55M	1.46M	994.00K	4.26M	2.69M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.95M	653.00K	867.00K	455.00K	284.15K
Stockholders Equity	2.28M	2.11M	1.15M	4.33M	2.80M
Cash Flow
Free Cash Flow	-2.55M	-3.92M	-3.27M	-2.13M	-1.57M
Operating Cash Flow	-2.55M	-3.92M	-3.27M	-2.13M	-1.57M
Investing Cash Flow	89.00K	9.00K	-41.00K	-2.00K	-37.86K
Financing Cash Flow	4.55M	4.38M	0.00	3.71M	2.49M

Sareum Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SAR, the sentiment is Negative. The current price of 15 is below the 20-day moving average (MA) of 16.30, below the 50-day MA of 17.48, and below the 200-day MA of 17.59, indicating a bearish trend. The MACD of -0.67 indicates Positive momentum. The RSI at 40.84 is Neutral, neither overbought nor oversold. The STOCH value of 54.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SAR.

Sareum Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AREC	56 Neutral	£27.18M	-1.64	-204.29%	―	3.31%	21.91%
APTA	52 Neutral	£22.92M	-3.03	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POLB	49 Neutral	£29.61M	-1.92	-46.84%	―	―	―
IMM	46 Neutral	£36.70M	-3.00	-259.88%	―	―	―
FAB	44 Neutral	£17.50M	-9.67	-164.37%	―	-11.43%	23.40%
SAR	42 Neutral	£21.40M	-4.45	-202.14%	―	―	23.76%

Sareum Holdings Corporate Events

Sareum to Release Interim Results and Host Live Investor Presentation

Sareum Holdings said it will publish its unaudited interim financial results for the six months to 31 December 2025 on 12 March 2026. The update will give investors a mid-year view on the progress and financial health of the company as it advances its kinase inhibitor pipeline.

Alongside the figures, Sareum will host a live online investor presentation on the same day via the Investor Meet Company platform, open to existing and prospective shareholders. The event, which will be followed by the publication of the presentation on the company’s website, underscores Sareum’s efforts to broaden engagement and transparency with its retail and institutional investor base.

The most recent analyst rating on (GB:SAR) stock is a Hold with a £15.50 price target. To see the full list of analyst forecasts on Sareum Holdings stock, see the GB:SAR Stock Forecast page.

Sareum Restarts Phase 2-Enabling Toxicology Programme for Lead Autoimmune Drug SDC-1801

Sareum Holdings has restarted its Phase 2-enabling toxicology programme for SDC-1801, a selective TYK2/JAK1 inhibitor in development for autoimmune diseases with an initial focus on psoriasis, after appointing a leading global contract research organisation to run the long-term studies. Supported by preliminary pharmacokinetic work and funded from existing cash resources, the toxicology dosing phase is expected to finish by mid-2026, with the full Phase 2-enabling package targeted for completion by year-end, advancing the asset toward Phase 2 trials and reinforcing its potential as a once-daily, best-in-class oral therapy.

The most recent analyst rating on (GB:SAR) stock is a Hold with a £18.50 price target. To see the full list of analyst forecasts on Sareum Holdings stock, see the GB:SAR Stock Forecast page.

Sareum Holdings Passes All Resolutions at AGM, Strengthening Governance

Sareum Holdings plc announced that all resolutions at its Annual General Meeting were passed, including the re-election of directors and the approval of financial statements. This successful AGM underscores the company’s stable governance and shareholder support as it continues to advance its pipeline of kinase inhibitors, potentially enhancing its market position in the biotechnology sector.

Sareum Holdings Advances Pipeline and Strengthens Portfolio

Sareum Holdings has made significant progress in its pipeline, particularly with its lead program SDC-1801, which has completed Phase 1 trials and is advancing towards Phase 2 development despite a temporary setback in toxicology studies. The company has improved economic terms for its SRA737 asset and is actively pursuing partnerships to enhance its portfolio value. Additionally, Sareum’s new TYK2 neuroscience collaboration expands its potential in central nervous system diseases, positioning the company for future growth and value creation.